NCT02669511 is a Phase 2 clinical trial of PQR309 in Primary Central Nervous System Lymphoma, sponsored by PIQUR Therapeutics AG.

Who is sponsoring NCT02669511?

NCT02669511 is sponsored by PIQUR Therapeutics AG.

What drugs are being tested in NCT02669511?

Interventions in NCT02669511: PQR309.

What condition does NCT02669511 study?

NCT02669511 studies Primary Central Nervous System Lymphoma.

Is NCT02669511 still recruiting?

NCT02669511 is currently completed. Last updated 9 July 2019.

Last reviewed 2019-07-09 · How we verify

NCT02669511

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

Completed Phase 2 Last updated 9 July 2019

What this trial tests

Phase 2 trial testing PQR309 in Primary Central Nervous System Lymphoma in 21 participants. Completed in 12 January 2018.

Timeline

12 November 2015

Primary endpoint
12 January 2018

12 January 2018

Quick facts

Lead sponsor	PIQUR Therapeutics AG
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	21
Start date	12 November 2015
Primary completion	12 January 2018
Estimated completion	12 January 2018

Drugs / interventions tested

PQR309 — full drug profile →

Conditions studied

Primary Central Nervous System Lymphoma — all drugs for Primary Central Nervous System Lymphoma →

Sponsor

PIQUR Therapeutics AG — full company profile →

Who can join

18 and older, any sex, with Primary Central Nervous System Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

An open-label, non-randomized, two-stage, multicenter study evaluating clinical efficacy, safety and pharmacokinetics of PQR309 in patients with relapsed or refractory Primary Central Nervous System Lymphoma (PCNSL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease.
Panwar V, Singh A, Bhatt M, Tonk RK, et al · · 2023 · cited 628× · PMID 37779156 · DOI 10.1038/s41392-023-01608-z
Primary CNS Lymphoma.
Grommes C, DeAngelis LM. · · 2017 · cited 404× · PMID 28640701 · DOI 10.1200/jco.2017.72.7602
The Role of mTOR Signaling as a Therapeutic Target in Cancer.
Popova NV, Jücker M. · · 2021 · cited 183× · PMID 33572326 · DOI 10.3390/ijms22041743
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.
Wu X, Xu Y, Liang Q, Yang X, et al · · 2022 · cited 80× · PMID 35614940 · DOI 10.3389/fphar.2022.875372
Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.
Giulino-Roth L, van Besien HJ, Dalton T, Totonchy JE, et al · · 2017 · cited 73× · PMID 28619753 · DOI 10.1158/1535-7163.mct-16-0848
Introduction of novel agents in the treatment of primary CNS lymphoma.
Grommes C, Nayak L, Tun HW, Batchelor TT. · · 2019 · cited 61× · PMID 30423172 · DOI 10.1093/neuonc/noy193
Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?
Tarantelli C, Lupia A, Stathis A, Bertoni F. · · 2020 · cited 32× · PMID 32033478 · DOI 10.3390/ijms21031060
Immunometabolism in cancer: basic mechanisms and new targeting strategy.
Su R, Shao Y, Huang M, Liu D, et al · · 2024 · cited 28× · PMID 38755125 · DOI 10.1038/s41420-024-02006-2

Verify or expand the search:

Other trials of PQR309

Trials testing the same drug.

NCT02723877 — PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) · Phase 1, PHASE2 · completed

Other recruiting trials for Primary Central Nervous System Lymphoma

Currently open trials in the same condition.

NCT07350850 — A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Re · Phase 2 · recruiting
NCT06712810 — Q702 for the Treatment of Patients With Hematologic Malignancies · Phase 1 · recruiting
NCT06922604 — Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma · Phase 1 · recruiting
NCT06832267 — Rituximab-Methotrexate-Temozolomide-Thiotepa (RMTT) Regimen As First-line Therapy for PCNS DLBCL · NA · recruiting
NCT06475235 — Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL · Phase 1 · recruiting

Other PIQUR Therapeutics AG trials

Trials by the same sponsor.

NCT02483858 — Study of Oral PQR309 in Patients With Advanced Solid Tumors · Phase 1 · completed
NCT02723877 — PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02669511 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by PIQUR Therapeutics AG
Last refreshed: 9 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02669511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing